Atrium Therapeutics, Inc. Common Stock Asset Resilience Ratio
Atrium Therapeutics, Inc. Common Stock asset resilience ratio. Atrium Therapeutics, Inc. Common Stock (RNA) has an Asset Resilience Ratio of 68.61% as of June 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See RNA defensive asset coverage days to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Atrium Therapeutics, Inc. Common Stock (2020–2024)
Asset resilience ratio of Atrium Therapeutics, Inc. Common Stock from 2020 to 2024. This chart shows how Atrium Therapeutics, Inc. Common Stock's Asset Resilience Ratio has changed over time. Read Atrium Therapeutics, Inc. Common Stock (RNA) financial obligations for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Atrium Therapeutics, Inc. Common Stock's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see Atrium Therapeutics, Inc. Common Stock total assets.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $939.24 Million | 68.61% |
| Total Liquid Assets | $939.24 Million | 68.61% |
Asset Resilience Insights
- Very High Liquidity: Atrium Therapeutics, Inc. Common Stock maintains exceptional liquid asset reserves at 68.61% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Atrium Therapeutics, Inc. Common Stock Industry Peers by Asset Resilience Ratio
Compare Atrium Therapeutics, Inc. Common Stock's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Hyloris Developmentsen Sa
BR:HYL |
Biotechnology | 1.36% |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
Oruka Therapeutics, Inc.
NASDAQ:ORKA |
Biotechnology | 53.11% |
|
Gempharmatech Co. Ltd. A
SHG:688046 |
Biotechnology | 23.95% |
|
Vor Biopharma Inc
NASDAQ:VOR |
Biotechnology | 74.48% |
|
Inventiva S.A
PA:IVA |
Biotechnology | 52.73% |
|
Sunmax Biotechnology Co Ltd
TWO:4728 |
Biotechnology | 10.53% |
|
Guangdong VTR Bio-Tech Co Ltd
SHE:300381 |
Biotechnology | 4.98% |
Atrium Therapeutics, Inc. Common Stock Asset Resilience Ratio by Year (2020–2024)
Atrium Therapeutics, Inc. Common Stock asset resilience ratio by year from 2020 to 2024. The table below shows the annual Asset Resilience Ratio data for Atrium Therapeutics, Inc. Common Stock.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 81.95% | $1.28 Billion | $1.56 Billion | +16.68pp |
| 2023-12-31 | 65.27% | $410.27 Million | $628.55 Million | +22.95pp |
| 2022-12-31 | 42.32% | $270.33 Million | $638.80 Million | +22.42pp |
| 2021-12-31 | 19.90% | $85.09 Million | $427.58 Million | +17.90pp |
| 2020-12-31 | 2.00% | $6.68 Million | $333.90 Million | -- |
About Atrium Therapeutics, Inc. Common Stock
Atrium Therapeutics, Inc., a biopharmaceutical company, focuses on delivering ribonucleic acid (RNA) therapeutics to the heart to transform the care for people living with cardiomyopathies. The company's development stage product candidates include ATR 1072, a siRNA-based therapy targeting PRKAG2 for the treatment of PRKAG2 syndrome; and ATR 1086, a siRNA-based therapy targeting PLN for the treat… Read more